Please enable JavaScript to continue using this application.

Compare $CADL vs $XGN | Chartloom

Compare

$CADL vs $XGN

Candel Therapeutics Inc · Exagen Inc

CADL

Candel Therapeutics Inc

XGN

Exagen Inc

Compare $CADL vs $XGN

Comparing Candel Therapeutics Inc and Exagen Inc

CADLCandel Therapeutics Inc

XGNExagen Inc

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

XGNExagen Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.63x

Rev growth (TTM)

20.8%

YTD performance

39.4%

52W performance

-23.3%

FCF yield

-3.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CADL

XGN

Detailed metrics comparison

CADL

Candel Therapeutics Inc

XGN

Exagen Inc

Market Cap

CADL$728M

XGN$203M

Enterprise Value

CADL$575M

XGN$204M

Price

CADL$9.94

XGN$8.42

P/E Ratio

CADLN/A

XGNN/A

P/S Ratio

CADL6,281.93x

XGN2.86x

EV/Sales

CADL5,042.14x

XGN2.87x

EV/EBITDA

CADL0.00x

XGN0.00x

P/B Ratio

CADL6.18x

XGN16.60x

P/FCF Ratio

CADLN/A

XGNN/A

EV/FCF

CADL-10.02x

XGN-26.94x

PEG Ratio

CADLN/A

XGNN/A

Forward P/E (NTM)

CADLN/A

XGNN/A

Forward P/S (NTM)

CADLN/A

XGN2.63x

Revenue (TTM)

CADL$0

XGN$71M

Revenue Growth (YoY)

CADLN/A

XGN20.8%

Forward Rev Growth

CADL371.1%

XGN10.1%

Gross Margin (TTM)

CADL0.0%

XGN58.6%

Operating Margin (TTM)

CADL0.0%

XGN0.0%

EBITDA Margin (TTM)

CADL0.0%

XGN-15.1%

Net Margin (TTM)

CADL0.0%

XGN-26.6%

FCF Margin (TTM)

CADLN/A

XGN-10.7%

Net Income (TTM)

CADL$-89M

XGN$-19M

FCF (TTM)

CADL$-57M

XGN$-8M

EPS (TTM)

CADL-$1.19

XGN-$0.78

ROE (TTM)

CADL-8938.0%

XGN-12162.0%

ROA (TTM)

CADL-5631.0%

XGN-3368.0%

ROIC (TTM)

CADL-6512.0%

XGN-4566.0%

Cash

CADL$202M

XGN$25M

Debt

CADL$48M

XGN$26M

Net Cash/Debt

CADL$154M

XGN$-959K

Current Ratio (TTM)

CADL16.09x

XGN3.18x

Quick Ratio (TTM)

CADL15.89x

XGN2.75x

Debt/Equity (TTM)

CADL0.38x

XGN2.09x

Debt/Assets (TTM)

CADL0.0%

XGN0.0%

Interest Coverage (TTM)

CADLN/A

XGNN/A

Net Debt/EBITDA (TTM)

CADL0.00x

XGN0.00x

Beta

CADL-0.28

XGN2.28

52W Performance

CADL57.8%

XGN-23.3%

YTD Performance

CADL82.7%

XGN39.4%

% from 52W High

CADL-29.0%

XGN-31.2%

% from 52W Low

CADL128.5%

XGN225.1%

Asset Turnover (TTM)

CADL0.00x

XGN1.27x

FCF Yield (TTM)

CADL-7.9%

XGN-3.7%

Earnings Yield (TTM)

CADL-12.2%

XGN-9.3%

Dividend Yield (TTM)

CADLN/A

XGNN/A

Rule of 40

CADL0.0

XGN10.2

EV/GP/RG

CADLN/A

XGN0.55

Ticker research

View CADL research View XGN research

Metric	CADL Candel Therapeutics Inc	XGN Exagen Inc
Market & Valuation
Market Cap	$728M	$203M
Enterprise Value	$575M	$204M
Price	$9.94	$8.42
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	2.86x
EV/Sales	5,042.14x	2.87x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	16.60x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-26.94x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.63x
Revenue & Growth
Revenue (TTM)	$0	$71M
Revenue Growth (YoY)	N/A	20.8%
Forward Rev Growth	371.1%	10.1%
Profitability
Gross Margin (TTM)	0.0%	58.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-15.1%
Net Margin (TTM)	0.0%	-26.6%
FCF Margin (TTM)	N/A	-10.7%
Net Income (TTM)	$-89M	$-19M
FCF (TTM)	$-57M	$-8M
EPS (TTM)	-$1.19	-$0.78
ROE (TTM)	-8938.0%	-12162.0%
ROA (TTM)	-5631.0%	-3368.0%
ROIC (TTM)	-6512.0%	-4566.0%
Financial Health
Cash	$202M	$25M
Debt	$48M	$26M
Net Cash/Debt	$154M	$-959K
Current Ratio (TTM)	16.09x	3.18x
Quick Ratio (TTM)	15.89x	2.75x
Debt/Equity (TTM)	0.38x	2.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.28
52W Performance	57.8%	-23.3%
YTD Performance	82.7%	39.4%
% from 52W High	-29.0%	-31.2%
% from 52W Low	128.5%	225.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.27x
FCF Yield (TTM)	-7.9%	-3.7%
Earnings Yield (TTM)	-12.2%	-9.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	10.2
EV/GP/RG	N/A	0.55
Ticker research	View CADL research	View XGN research

Valuation

P/S Ratio

XGN

2.86x

CADL

6,281.93x

EV/FCF

XGN

-26.94x

CADL

-10.02x

Growth & revenue

Revenue Growth TTM

XGN

20.8%

Forward Revenue Growth

CADL

371.1%

XGN

10.1%

Profitability & performance

Gross Margin

XGN

58.6%

CADL

0.0%

ROE

CADL

-8938.0%

XGN

-12162.0%

FCF Yield %

XGN

-3.7%

CADL

-7.9%

52-Week Performance

CADL

57.8%

XGN

-23.3%

Detailed metrics comparison

CADL

Candel Therapeutics Inc

XGN

Exagen Inc

Market Cap

CADL$728M

XGN$203M

Enterprise Value

CADL$575M

XGN$204M

Price

CADL$9.94

XGN$8.42

P/E Ratio

CADLN/A

XGNN/A

P/S Ratio

CADL6,281.93x

XGN2.86x

EV/Sales

CADL5,042.14x

XGN2.87x

EV/EBITDA

CADL0.00x

XGN0.00x

P/B Ratio

CADL6.18x

XGN16.60x

P/FCF Ratio

CADLN/A

XGNN/A

EV/FCF

CADL-10.02x

XGN-26.94x

PEG Ratio

CADLN/A

XGNN/A

Forward P/E (NTM)

CADLN/A

XGNN/A

Forward P/S (NTM)

CADLN/A

XGN2.63x

Revenue (TTM)

CADL$0

XGN$71M

Revenue Growth (YoY)

CADLN/A

XGN20.8%

Forward Rev Growth

CADL371.1%

XGN10.1%

Gross Margin (TTM)

CADL0.0%

XGN58.6%

Operating Margin (TTM)

CADL0.0%

XGN0.0%

EBITDA Margin (TTM)

CADL0.0%

XGN-15.1%

Net Margin (TTM)

CADL0.0%

XGN-26.6%

FCF Margin (TTM)

CADLN/A

XGN-10.7%

Net Income (TTM)

CADL$-89M

XGN$-19M

FCF (TTM)

CADL$-57M

XGN$-8M

EPS (TTM)

CADL-$1.19

XGN-$0.78

ROE (TTM)

CADL-8938.0%

XGN-12162.0%

ROA (TTM)

CADL-5631.0%

XGN-3368.0%

ROIC (TTM)

CADL-6512.0%

XGN-4566.0%

Cash

CADL$202M

XGN$25M

Debt

CADL$48M

XGN$26M

Net Cash/Debt

CADL$154M

XGN$-959K

Current Ratio (TTM)

CADL16.09x

XGN3.18x

Quick Ratio (TTM)

CADL15.89x

XGN2.75x

Debt/Equity (TTM)

CADL0.38x

XGN2.09x

Debt/Assets (TTM)

CADL0.0%

XGN0.0%

Interest Coverage (TTM)

CADLN/A

XGNN/A

Net Debt/EBITDA (TTM)

CADL0.00x

XGN0.00x

Beta

CADL-0.28

XGN2.28

52W Performance

CADL57.8%

XGN-23.3%

YTD Performance

CADL82.7%

XGN39.4%

% from 52W High

CADL-29.0%

XGN-31.2%

% from 52W Low

CADL128.5%

XGN225.1%

Asset Turnover (TTM)

CADL0.00x

XGN1.27x

FCF Yield (TTM)

CADL-7.9%

XGN-3.7%

Earnings Yield (TTM)

CADL-12.2%

XGN-9.3%

Dividend Yield (TTM)

CADLN/A

XGNN/A

Rule of 40

CADL0.0

XGN10.2

EV/GP/RG

CADLN/A

XGN0.55

Ticker research

View CADL research View XGN research

Metric	CADL Candel Therapeutics Inc	XGN Exagen Inc
Market & Valuation
Market Cap	$728M	$203M
Enterprise Value	$575M	$204M
Price	$9.94	$8.42
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	2.86x
EV/Sales	5,042.14x	2.87x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	16.60x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-26.94x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.63x
Revenue & Growth
Revenue (TTM)	$0	$71M
Revenue Growth (YoY)	N/A	20.8%
Forward Rev Growth	371.1%	10.1%
Profitability
Gross Margin (TTM)	0.0%	58.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-15.1%
Net Margin (TTM)	0.0%	-26.6%
FCF Margin (TTM)	N/A	-10.7%
Net Income (TTM)	$-89M	$-19M
FCF (TTM)	$-57M	$-8M
EPS (TTM)	-$1.19	-$0.78
ROE (TTM)	-8938.0%	-12162.0%
ROA (TTM)	-5631.0%	-3368.0%
ROIC (TTM)	-6512.0%	-4566.0%
Financial Health
Cash	$202M	$25M
Debt	$48M	$26M
Net Cash/Debt	$154M	$-959K
Current Ratio (TTM)	16.09x	3.18x
Quick Ratio (TTM)	15.89x	2.75x
Debt/Equity (TTM)	0.38x	2.09x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.28
52W Performance	57.8%	-23.3%
YTD Performance	82.7%	39.4%
% from 52W High	-29.0%	-31.2%
% from 52W Low	128.5%	225.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.27x
FCF Yield (TTM)	-7.9%	-3.7%
Earnings Yield (TTM)	-12.2%	-9.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	10.2
EV/GP/RG	N/A	0.55
Ticker research	View CADL research	View XGN research